Paralleling observations in the total IBD cohort, standard blood or fecal markers of inflammation (Hb, white blood cell counts, CRP, fecal calprotectin, fecal S100A12) in patients with future relapse did not significantly differ from those with future stable remission (Table 1, Supplementary Table S1). This evidence concerns the gene CRP and inflammatory bowel disease.